Brain CAR T Cell News
City of Hope Publications
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
Driven in part by the plight of his patients and his father, chief of neurosurgery Behnam Badie, M.D., spends nearly as much time in the laboratory as he does in the operating room. He wants to help not just today's patients, but tomorrow's.
Say the words “brain tumor” and most people will likely think of cancer. But there’s reason for optimism - recent advances in screening and treatment, such as CAR T cell therapy, mean patient outcomes and quality of life are continuing to improve.
A research team led by Christine Brown, Ph.D., and a clinical team headed by Behnam Badie, M.D., has received a $12.8 million grant from the CIRM to fund a phase 1 chimeric antigen receptor (CAR) T cell trial targeting an aggressive brain cancer called malignant glioma, which includes glioblastoma.
City of Hope researchers have found that using CAR T therapy, a type of immunotherapy, can be effective in the treatment of glioblastoma — one of the most aggressive brain tumors known to medicine.
T cells were genetically modified in a lab by City of Hope researchers and trained to target specific receptors on patients’ brain tumors - part of an emerging approach to cancer care called immunotherapy.
Studies presented by City of Hope physicians and researchers at the annual meeting of the American Association for Cancer Research, could influence future approaches to drug-resistant cancers, treating aggressive brain cancers, recruiting diverse populations for research, and targeted therapies.
City of Hope researchers have seen initial success treating brain cancer patients with CAR T cell therapy, yet questions still linger about what exactly happens to these cells once they disperse through the brain. A new imaging technique may be the answer.
City of Hope case study published in the New England Journal of Medicine reported treatment with reengineered CAR T cells dramatically improved quality of life for patient with recurrent glioblastoma.
One of but a few centers in the United States offering human studies in CAR–T cell therapy, City of Hope is the only center investigating CAR T cells in injection form administered directly to brain tumors.
Soon, brain cancer will be treated differently. Just ask scientist Christine Brown, Ph.D., associate director of the T Cell Immunotherapy Laboratory at City of Hope. Brown is on the forefront of a specific kind of immunotherapy: CAR T cell therapy. Here, Brown tells us how this type of therapy works and what it could mean for future treatment.
Diane Peacock uses May, Brain Tumor Awareness Month, as a time to recognize, remember and spread awareness about brain cancer - the deadly disease that took her son’s life when he was just four days shy of his 19th birthday.
Patients have long needed a better treatment option for brain tumors. As we enter 2016, just such an option is taking shape: CAR T cell therapy.
Brain cancer is one of the toughest foes a doctor can face. It’s a tenacious form of cancer, inoperable in some cases and lethal in many. But at City of Hope, researchers are exploring new ways to conquer the most serious types of brain tumors in a clinical trial that deploys a patient’s own modified T cells to target cancer at the tumor site.